Regeneron And Geisinger Get Ambitious In Next-Gen Genomics
Regeneron and Geisinger’s new collaboration to identify genetic variants and apply that knowledge to drug discovery and patient care is pharma’s most ambitious effort to date to exploit next-generation genomics, but its impact on drug discovery productivity won’t be known for years.
You may also be interested in...
Regeneron On Genetics R&D: 'It's Our Oxygen'
Regeneron is pointing to early research in genetics as the lifeline that will deliver new drugs into the clinic as Eylea matures, new blockbusters have yet to materialize and investors grow restless.
A Researcher’s Hope For Sequencing: Rare Genetic Variants Yield New Drugs
Columbia University Professor Wendy Chung’s work on identifying the causative mutations underlying ultra-rare diseases such as hereditary pulmonary hypertension puts a real-world perspective on pharma’s increasing interest in genomic analysis as a tool for drug discovery.
Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond
The better-than-expected performance of Regeneron’s first significant commercial drug, Eylea, has fueled the company’s ambitions to build a sustainable, risk-adjusted portfolio based on a mix of best-in-class and first-in-class new drugs. Getting to this point took a mixture of perseverance, astute science, opportunism, and savvy partnering.